PURPOSE: An overview of the Rapid Learning methodology, its results, and the potential impact on radiotherapy. MATERIAL AND RESULTS: Rapid Learning methodology is divided into four phases. In the data phase, diverse data are collected about past patients, treatments used, and outcomes. Innovative information technologies that support semantic interoperability enable distributed learning and data sharing without additional burden on health care professionals and without the need for data to leave the hospital. In the knowledge phase, prediction models are developed for new data and treatment outcomes by applying machine learning methods to data. In the application phase, this knowledge is applied in clinical practice via novel decision support systems or via extensions of existing models such as Tumour Control Probability models. In the evaluation phase, the predictability of treatment outcomes allows the new knowledge to be evaluated by comparing predicted and actual outcomes. CONCLUSION: Personalised or tailored cancer therapy ensures not only that patients receive an optimal treatment, but also that the right resources are being used for the right patients. Rapid Learning approaches combined with evidence based medicine are expected to improve the predictability of outcome and radiotherapy is the ideal field to study the value of Rapid Learning. The next step will be to include patient preferences in the decision making.
PURPOSE: An overview of the Rapid Learning methodology, its results, and the potential impact on radiotherapy. MATERIAL AND RESULTS: Rapid Learning methodology is divided into four phases. In the data phase, diverse data are collected about past patients, treatments used, and outcomes. Innovative information technologies that support semantic interoperability enable distributed learning and data sharing without additional burden on health care professionals and without the need for data to leave the hospital. In the knowledge phase, prediction models are developed for new data and treatment outcomes by applying machine learning methods to data. In the application phase, this knowledge is applied in clinical practice via novel decision support systems or via extensions of existing models such as Tumour Control Probability models. In the evaluation phase, the predictability of treatment outcomes allows the new knowledge to be evaluated by comparing predicted and actual outcomes. CONCLUSION: Personalised or tailored cancer therapy ensures not only that patients receive an optimal treatment, but also that the right resources are being used for the right patients. Rapid Learning approaches combined with evidence based medicine are expected to improve the predictability of outcome and radiotherapy is the ideal field to study the value of Rapid Learning. The next step will be to include patient preferences in the decision making.
Authors: Borja Martínez-Pérez; Isabel de la Torre-Díez; Miguel López-Coronado; Beatriz Sainz-de-Abajo; Montserrat Robles; Juan Miguel García-Gómez Journal: J Med Syst Date: 2014-01-08 Impact factor: 4.460
Authors: Philippe Lambin; Ralph T H Leijenaar; Timo M Deist; Jurgen Peerlings; Evelyn E C de Jong; Janita van Timmeren; Sebastian Sanduleanu; Ruben T H M Larue; Aniek J G Even; Arthur Jochems; Yvonka van Wijk; Henry Woodruff; Johan van Soest; Tim Lustberg; Erik Roelofs; Wouter van Elmpt; Andre Dekker; Felix M Mottaghy; Joachim E Wildberger; Sean Walsh Journal: Nat Rev Clin Oncol Date: 2017-10-04 Impact factor: 66.675
Authors: Stanley H Benedict; Karen Hoffman; Mary K Martel; Amy P Abernethy; Anthony L Asher; Jacek Capala; Ronald C Chen; Bhisham Chera; Jennifer Couch; James Deye; Jason A Efstathiou; Eric Ford; Benedick A Fraass; Peter E Gabriel; Vojtech Huser; Brian D Kavanagh; Deepak Khuntia; Lawrence B Marks; Charles Mayo; Todd McNutt; Robert S Miller; Kevin L Moore; Fred Prior; Erik Roelofs; Barry S Rosenstein; Jeff Sloan; Anna Theriault; Bhadrasain Vikram Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-01 Impact factor: 7.038
Authors: Barry S Rosenstein; Catharine M West; Søren M Bentzen; Jan Alsner; Christian Nicolaj Andreassen; David Azria; Gillian C Barnett; Michael Baumann; Neil Burnet; Jenny Chang-Claude; Eric Y Chuang; Charlotte E Coles; Andre Dekker; Kim De Ruyck; Dirk De Ruysscher; Karen Drumea; Alison M Dunning; Douglas Easton; Rosalind Eeles; Laura Fachal; Sara Gutiérrez-Enríquez; Karin Haustermans; Luis Alberto Henríquez-Hernández; Takashi Imai; George D D Jones; Sarah L Kerns; Zhongxing Liao; Kenan Onel; Harry Ostrer; Matthew Parliament; Paul D P Pharoah; Timothy R Rebbeck; Christopher J Talbot; Hubert Thierens; Ana Vega; John S Witte; Philip Wong; Frederic Zenhausern Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-15 Impact factor: 7.038